Renal

Clear Cell

Localized

T1b or greater (has not spread beyond the kidney)

No Prior Systemic Therapy

IRB# 20148
X1184-313: Phase 3 Randomized Study of Cabozantinib with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab

IRB# 19991
A0317004: PD-Inhibitor (Nivolumab) and Ipilimumab Followed By Nivolumab vs VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer (PDIGREE)

IRB# 19661
EA8143: Phase 3 Randomized Study Comparing perioperative Nivolumab vs Observation in Patients with Localized RCC Undergoing Nephrectomy (PROSPER)

IRB# 19283
Xynomic Pazopanib +/- Abexinostate in Patients with locally advanced or Metastatic RCC

IRB# 17027
A Phase 2, Fast Real-time Assessment of Combination Therapies in Immunono.

Metastatic/locally advanced

Clear Cell

Nephrectomy Candidate

No prior VEGF. Up to 1 prior cytokine or immune checkpoint inhibitor

IRB# 19283
Xynomic Pazopanib +/- Abexinostate in Patients with locally advanced or Metastatic RCC

IRB# 17027
A Phase 2, Fast Real-time Assessment of Combination Therapies in Immunono.

Prior Systemic Therapy

Track 2: Prior treatment with anti-PD-1, anti-PD-L1 or anti-CTLA-4

IRB# 19661
EA8143: Phase 3 Randomized Study Comparing perioperative Nivolumab vs Observation in Patients with Localized RCC Undergoing Nephrectomy (PROSPER)

IRB# 19283
Xynomic Pazopanib +/- Abexinostate in Patients with locally advanced or Metastatic RCC

IRB# 17027
A Phase 2, Fast Real-time Assessment of Combination Therapies in Immunono.

Progression on anti-PD-1/PD-L1 mAb monotherapy or in combo w/ other therapies

Non-Clear Cell

Papillary Renal Carcinoma

CROSS-DISEASE TRIALS

IRB# 19992
EAY 131 (MATCH)

IRB# 18084
S1609 (DART)

http://www.ohsu.edu/research/rda/so/knight.php

Key

Open for enrollment

In development

Enrollment on hold

31JAN2020